PMA device
Claire OCT System
Perimeter Medical Imaging Ai, Inc. · Oct Imaging System With Ai/Ml Software For Adjunctive Detection Of Breast Cancer (SHH, Class III) · First FDA decision Mar 3, 2026, newest Aug 10, 2026Breast cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
0
Naming "Claire OCT"
MAUDE reports
0
Brand "Claire OCT", since 2015
PubMed studies
0
Mentioning "Claire OCT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Claire OCT System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Claire OCT SystemPMA supplement
P250008-S001 · Decided Aug 10, 2026 · 150 days after receipt · Normal 180 Day Track No User Fee
Device type: OCT imaging system with AI/ML software for adjunctive detection of breast cancer (SHH) · General & Plastic Surgery
- Claire OCT SystemBreakthroughPMA
P250008 · Decided Mar 3, 2026 · 355 days after receipt
Device type: OCT imaging system with AI/ML software for adjunctive detection of breast cancer (SHH) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Positron Emission Tomography (FDG) for Breast CancerNational analysisReview closedCAG-00094NUpdated Sep 15, 2026
- Screening Pap Smears and Pelvic Examinations for Early Detection of Cervical or Vaginal CancerNational determinationOn the books210.2Updated Sep 30, 2025
- FDG PET for Breast Cancer (Replaced with Section 220.6.17) - RETIREDNational determinationOn the books220.6.10Updated Jun 7, 2024
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- Breast Imaging: Breast Echography (Sonography)/Breast MRI/DuctographyLocal determinationIn effectL33585Wellpoint FederalUpdated Jul 14, 2026
- MolDX: EndoPredict Breast Cancer Gene Expression TestLocal determinationIn effectL37356CGS Administrators, LLCUpdated Apr 6, 2026
- MolDX: Breast Cancer Assay: Prosigna®Local determinationIn effectL36425CGS Administrators, LLCUpdated Mar 9, 2026
- MolDX: Breast Cancer Index® (BCI) Gene Expression TestLocal determinationIn effectL37913WPS Insurance CorporationUpdated Feb 20, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Claire OCT", any status and sponsor, newest update first.
No registered device study names "Claire OCT".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Claire OCT", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SHH
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Claire OCT"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.